InsidersTradesSigma
Total declarations
Company
▲ Purchases (1 ops.)
▼ Sales (1 ops.)
Insider track record
CFODisclosed buys
1
Disclosed sells
1
T+90 hit rate
100%
T+90 mean return
+39.2%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the full record of transactions filed by Reardon Tighe, Chief Financial Officer. Officer active across 1 company, notably Janux Therapeutics, Inc.. Aggregated, 4 reports have been logged. Breakdown: 1 buy · 1 sell. Total volume traded: €11.3m. History available since 13 November 2023. The latest transaction was disclosed on 3 June 2024 (Cession). Regulator: SEC (Form 4). All data is openly available.
Declarations4 total
131,196 shares@ US$54.7558.5% of flowCommon StockSEC:0001415889-24-015676:0
849,854 shares@ US$5.8741.5% of flowCommon StockSEC:0001209191-23-055352:0
Ideal exit: 9 Aug 2024 (T+270)
2,696,843 sharesCommon StockSEC:0001209191-21-041041:0
2,696,843 sharesCommon StockSEC:0001209191-21-041041
4 of 4 declarations
About Reardon Tighe
Tighe Reardon serves as the Acting Chief Financial Officer at Janux Therapeutics, Inc. He is responsible for overseeing the company's financial operations, including budgeting and financial analysis. His expertise contributes to the effective management of financial resources and strategic decision-making.
